Triamcinolone Acetonide Extended-Release Injectable Suspension (Zilretta™ )

Zilretta is covered only for the FDA‑approved indication—a single 32 mg intra‑articular injection for knee osteoarthritis—off‑label uses and prior receipt of Zilretta are excluded. Approval requires radiologic confirmation of knee osteoarthritis, documentation that the patient has not previously received Zilretta, evidence of inadequate response to a prior intra‑articular corticosteroid injection, and supporting records (radiology report, medication/treatment history).

"FDA-approved indication: Zilretta is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee."

Sign up to see full coverage criteria, indications, and limitations.